Albireo and genpharm announce agreement to commercialize bylvay™ (odevixibat) in saudi arabia and the gulf region

– bylvay is approved in the u.s. and eu as only once-daily drug indicated for patients with pfic –

ALBO Ratings Summary

ALBO Quant Ranking